Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials

Currently approved antipsychotics do not adequately treat negative symptoms (NS), which are a major determinant of functional disability in schizophrenia. KarXT, an M1 /M4 preferring muscarinic receptor agonist, has shown efficacy as a broad-spectrum monotherapy for the treatment of schizophrenia in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Schizophrenia research 2024-12, Vol.274, p.57-65
Hauptverfasser:	Horan, William P., Targum, Steven D., Claxton, Amy, Kaul, Inder, Yohn, Samantha E., Marder, Stephen R., Miller, Andrew C., Brannan, Stephen K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Adult Antipsychotic Agents - therapeutic use Clinical trial Dibenzocycloheptenes Double-Blind Method Female Humans Male Middle Aged Monotherapy Muscarinic Prominent negative symptoms Psychiatric Status Rating Scales Schizophrenia Schizophrenia - drug therapy Schizophrenia - physiopathology Schizophrenic Psychology Treatment effects Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!